Zimbabwe sits on a high plateau with altitudes between 1200 and 1600 meters across most of the country, which moderates temperatures but does not eliminate tropical disease vectors present in lower-lying areas like the Zambezi Valley, Lake Kariba shores, and the Lowveld regions including Gonarezhou National Park. The country experiences a rainy season from November through March when mosquito populations peak, followed by a cooler dry season from May to August. Understanding these geographical and seasonal patterns determines which health precautions apply to specific itineraries.
Malaria transmission occurs year-round in areas below 1200 meters elevation, including the entire Zambezi Valley encompassing Victoria Falls, Mana Pools National Park, Lake Kariba, and Matusadona National Park, the Lowveld region containing Gonarezhou National Park and parts of the Save Valley Conservancy, and the southeastern border areas near Beitbridge. The Plasmodium falciparum species, which accounts for approximately 99 percent of malaria cases in Zimbabwe according to Zimbabwe Ministry of Health surveillance data from 2019-2022, is the predominant and most severe form. Harare, Bulawayo, the Eastern Highlands including Nyanga and Chimanimani, and the Highveld plateau areas above 1200 meters have minimal to no malaria transmission. Travelers spending time in both high-altitude cities and low-altitude parks require chemoprophylaxis for the entirety of their trip since protection must begin before exposure and continue after leaving endemic areas.
The United States Centers for Disease Control and Prevention recommends atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine for malaria chemoprophylaxis in Zimbabwe. Atovaquone-proguanil requires daily dosing starting one to two days before entering a malaria zone, throughout exposure, and for seven days after leaving. Doxycycline requires daily dosing starting one to two days before, during, and for four weeks after exposure. Mefloquine requires weekly dosing starting two weeks before, during, and for four weeks after exposure. Tafenoquine requires a loading dose three days before travel, weekly during exposure, and a final dose continuing the weekly schedule after departure. Consultation with a physician familiar with current resistance patterns and individual contraindications is necessary since no universal recommendation applies to all travelers. Zimbabwe has documented chloroquine resistance since the 1980s, making chloroquine ineffective. Travelers should obtain prescriptions and medications before departure since counterfeit antimalarials circulate within Zimbabwe's pharmaceutical supply chain.
Yellow fever does not occur in Zimbabwe. The country requires proof of yellow fever vaccination only from travelers arriving from or transiting through countries with risk of yellow fever transmission. Travelers arriving directly from countries without yellow fever, including most of Europe, North America, and Asia, do not need yellow fever vaccination for Zimbabwe entry. Travelers coming from endemic countries in tropical Africa or South America must present a valid International Certificate of Vaccination documenting yellow fever vaccine received at least 10 days before arrival. The certificate remains valid for life following World Health Organization standards implemented in 2016. Travelers transiting through Addis Ababa, Nairobi, or Johannesburg from non-endemic countries do not require vaccination since these cities are not considered transmission zones.
Typhoid fever occurs throughout Zimbabwe due to water and food contamination. The Zimbabwe Ministry of Health reported typhoid outbreaks in Harare suburbs including Mbare, Kuwadzana, and Glen View between 2011 and 2012, with over 2000 cases documented. Sporadic cases continue in areas with inadequate water treatment and sanitation infrastructure. The Vi polysaccharide vaccine provides protection for two years and requires a single injection. The Ty21a oral vaccine requires four capsules taken on alternate days and provides protection for five years. Both vaccines require completion at least two weeks before potential exposure. Vaccination does not guarantee protection since efficacy ranges between 50 and 80 percent depending on subsequent exposure intensity.
Hepatitis A transmission occurs throughout Zimbabwe through contaminated food and water. The Zimbabwe National AIDS Council and Ministry of Health report hepatitis A seroprevalence approaching 90 percent in the adult population, indicating widespread historical exposure. Travelers from countries with high sanitation standards typically lack immunity. The hepatitis A vaccine requires two doses separated by six to twelve months for long-term protection, though a single dose provides immunity for at least 12 months. Travelers departing within two weeks can receive immune globulin alongside vaccine for immediate passive immunity, though this practice has declined since vaccine effectiveness improvements.
Hepatitis B transmission occurs through sexual contact, blood exposure, and contaminated medical equipment. Zimbabwe's hepatitis B surface antigen prevalence ranges between 5 and 10 percent in the general population based on surveys conducted between 2005 and 2015, placing the country in intermediate endemicity. The three-dose hepatitis B vaccine series requires six months to complete on the standard schedule, with doses at zero, one, and six months. An accelerated schedule administering doses at zero, seven, and twenty-one days exists for travelers with limited preparation time, though a fourth dose at 12 months is recommended for sustained immunity. The combined hepatitis A and hepatitis B vaccine requires three doses over six months and suits travelers needing protection against both diseases.
Rabies exists throughout Zimbabwe in domestic dogs, wildlife including jackals and mongooses, and bat populations. The Zimbabwe Ministry of Health documented 68 human rabies deaths in 2019, though underreporting likely occurs in rural areas. Domestic dogs account for approximately 90 percent of human exposures. The pre-exposure rabies vaccine series requires three doses administered on days zero, seven, and twenty-one or twenty-eight. Pre-exposure vaccination does not eliminate the need for post-exposure treatment but reduces the number of required doses from four to two and eliminates the need for rabies immune globulin, which is frequently unavailable in Zimbabwe. Travelers planning extended time in rural areas, working with animals, or engaging in activities like caving where bat contact may occur should consider pre-exposure vaccination. Post-exposure treatment requires immediate wound washing with soap and water for 15 minutes followed by medical evaluation, though locating appropriate treatment facilities in Zimbabwe presents challenges outside Harare and Bulawayo.
Routine vaccinations including measles-mumps-rubella, diphtheria-tetanus-pertussis, varicella, polio, and annual influenza should be current before travel. Zimbabwe experienced measles outbreaks in 2010 with over 10,000 cases and again in 2019 with clusters in Manicaland Province. Adults born after 1957 who have not received two doses of measles-containing vaccine should complete the series. Polio vaccination should be current since Zimbabwe reported circulating vaccine-derived poliovirus type 2 cases in 2021, though the outbreak was contained. Tetanus boosters are required every 10 years, or every five years following a high-risk wound.
Tuberculosis incidence in Zimbabwe was 210 cases per 100,000 population in 2021 according to World Health Organization estimates. HIV co-infection drives tuberculosis transmission, with approximately 60 percent of tuberculosis patients testing HIV-positive. The BCG vaccine provides limited protection in adults and is not routinely recommended for travelers. Risk increases for healthcare workers and individuals with prolonged close contact with local populations in confined spaces. Tuberculosis is an airborne disease requiring no specific traveler precautions beyond avoiding obvious exposure to individuals with active cough illness.
Meningococcal meningitis occurs sporadically in Zimbabwe, though the country lies outside the African meningitis belt where epidemic transmission occurs during dry seasons. Outbreaks in Zimbabwe cluster during September through November when dry, dusty conditions prevail. A notable outbreak occurred in 2010 affecting Harare, Manicaland, and Mashonaland East provinces. The quadrivalent meningococcal vaccine covering serogroups A, C, W, and Y provides protection for approximately five years. Meningococcal B vaccine exists separately but is not routinely recommended for Zimbabwe since serogroup B causes minimal disease there.